Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Combined With ARX788 Neoadjuvant Treatment in HER2-positive Breast Cancer
NCT04983121Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in breast cancer, sponsored by Shengjing Hospital of China Medical University. Started Aug 2021; status: recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04983121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983121.